Bristol Myers Squibb committed US$14 billion to buy Karuna Therapeutics, just weeks after AbbVie paid $8.7 billion for Cerevel Therapeutics. The acquired muscarinic receptor modulators stand to become ...
Sumitomo Pharma Co. Ltd. has patented aminomethylcyclohexane derivatives acting as muscarinic M4 receptor antagonists. As such, they are described as potentially useful for the treatment of ...
Co. Ltd. has patented new muscarinic M4 receptor positive allosteric modulators (PAMs) potentially useful for the treatment of schizophrenia, bipolar disorder, Huntington’s, Alzheimer’s, inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results